NIH begins ZMapp trial; Sanofi nears EU nod with new insulin;

@FierceBiotech: From @FiercePharmAsia, Novartis' Japan unit hit with a 15-day sales ban. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: Vitae slammed as another BACE inhibitor trips and Boehringer halts Alzheimer's study. Report | Follow @JohnCFierce

@DamianFierce: While $MRK and $ACT embrace antibiotics, $AZN is tiptoeing out. Report | Follow @DamianFierce

> The National Institutes of Health has kicked off its clinical trial of Mapp Biopharmaceutical's ZMapp, a promising treatment for Ebola. More

> Sanofi's ($SNY) Toujeo, a long-acting insulin, secured an EU recommendation just days after picking up FDA approval, stoking the companies hopes of usurping the soon-to-come-off-patent Lantus. Story

> In a late-stage trial, the combination of Bristol-Myers Squibb's ($BMY) daclatasvir and Gilead Sciences' ($GILD) Sovaldi charted a 97% cure rate for hepatitis C patients who also have HIV. News

Medical Device News

@FierceMedDev: Exact Sciences beefs up sales and reimbursement efforts for colon cancer Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Boston Scientific launches upgraded endoscope, says it will reduce repeat procedures. Article | Follow @VarunSaxena2

@EmilyWFierce: Vigilant Biosciences reels in $5.5M for oral cancer test. More from FierceDiagnostics | Follow @EmilyWFierce

> Nikon to buy optical imaging player Optos for $400M in med tech expansion bid. Story

> UnitedHealth to require prior authorization for gynecological procedures amid morcellator pushback. More

> Device for remote and autonomous management of Parkinson's being tested in Europe. Article

Pharma News

@FiercePharma: ICYMI from FiercePharmaManufacturing: Impax reports significant jump in revenues as it gets plant problems behind it. Article | Follow @FiercePharma

@EricPFierce: FDA problems continue to pile up at Wockhardt Indian plant banned from shipping to the US. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: Pfizer, Novartis get MenB ACIP nod--but not the one they're really after. More from FierceVaccines | Follow @CarlyHFierce

> Pfizer, Novartis: CDC's MenB nod is too narrow. Item

> Sanofi's Toujeo gets the love from EU regulators that FDA withheld. Story

> Gilead looks overseas to guard profits for hep C blockbuster Sovaldi. Article

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.